On September 28, 2018, Zhai, Xin; Zhou, Yuhong; Gong, Ping; Jing, Tongfei; Lei, Hongrui; Guo, Ming; Xing, Lingyun published a patent.Electric Literature of 16230-24-3 The title of the patent was Tetrahydropyrido[4,3-d]pyrimidine derivative useful in treatment of ATX and EGFR related diseases and its preparation. And the patent contained the following:
The invention relates to tetrahydropyrido[4,3-d]pyrimidine derivative of formula I useful in treatment of ATX and EGFR related diseases and its preparation Compounds I, wherein L is O(CH2)m, S(CH2)m, NH(CH2) m, etc.; m is 0-4; P is O, S, NH, etc; R1 is C6-10 aryl or 5-10-membered heteroaryl (containing 1-3 heteroatoms selected from N, O and S); R3 is C1-6 alkyl, C2-6 alkenyl, C3-6 alkenyl amino, C6-10 aryl, etc.; their optical stereoisomers, pharmaceutically acceptable salts, solvates, or prodrug, are claimed. The inventive compound shows high inhibitory activity on ATX and EGFR, and can be applied in the drugs for preventing and/or treating the diseases caused by abnormal expression of ATX and EGFR, especially the drugs for preventing and/or treating fibrosis and cancer. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Electric Literature of 16230-24-3
The Article related to tetrahydropyrido pyrimidine preparation treatment atx egfr disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Electric Literature of 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics